European Urology - Hypoxia-Inducible Factor 1α Expression in Renal Cell Carcinoma Analyzed by Tissue Microarray
Friday, 01 December 2006
Volume 50, Issue 6, Pages 1272-1277 (December 2006) Abstract - Objectives: Angiogenesis is important for tumour progression and metastatic spread. Hypoxia-inducible factor 1α (HIF-1α) is a major factor regulating a number of other angiogenic factors.
read more
|
Long-Term Results of Cryoablation for Renal Cancer and Complex Renal Masses
Friday, 01 December 2006
BERKELEY, CA (UroToday.com) - In situ thermal destruction of renal masses through the creation of lethal cold temperatures has become an acceptable treatment option for patients with incidentally discovered small renal lesions. Few long-term studies have been published to examine the efficacy and safety of the procedure.
read more
|
Cost Trends For Oncological Renal Surgery: Support For a Laparoscopic Standard of Care
Tuesday, 28 November 2006
BERKELEY, CA (UroToday.com) - This report from the University of Michigan affirms the cost-effectiveness of the laparoscopic approach for oncological renal surgery. They analyzed direct variable costs, between 1998 and 2003, in patients undergoing radical or partial nephrectomy for tumor disease.
read more
|
Phase II Trial of Continuous Low-Dose Oral Cyclophosphamide and Celecoxib for Metastatic Renal Cell Carcinoma
Tuesday, 21 November 2006
BERKELEY, CA (UroToday.com) - Traditional chemotherapeutic regimens given at high doses in an intermittent fashion have demonstrated little to no activity in the treatment of metastatic renal cell carcinoma (RCC).
read more
|
√ Phase II Trial of Interferon in Combination with Thalidomide for Metastatic Renal Cell Carcinoma
Monday, 20 November 2006
√ Editor's Pick: BERKELEY, CA (UroToday.com) - Both thalidomide and -interferon (IFN) have been utilized as monotherapy in the treatment of patients with metastatic renal cell carcinoma (RCC), each with modest evidence of activity and acceptable toxicity profiles.
read more
|
Second Primary Malignancies Associated With Renal Cell Carcinoma Histological Subtypes
Monday, 20 November 2006
BERKELEY, CA (UroToday.com) - Past studies have suggested that there is a linkage between the development of renal cell carcinoma (RCC) and the incidence of other secondary malignancies, but this remains controversial. Rabbani and associates out of Memorial Sloan Kettering published a study that suggested that patients with papillary RCC had a higher risk of developing bladder and prostate cancer.
read more
|
European Urology - A Prospective Randomized EORTC Intergroup Phase 3 Study Comparing the Complications of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma
Friday, 17 November 2006
Abstract - Objectives: This study compared the complications and the cancer control of elective nephron-sparing surgery (NSS) and radical nephrectomy (RN) in patients with a small (≤5cm), solitary, low-stage N0 M0 tumour suspicious for renal cell carcinoma (RCC) and a normal contralateral kidney.
read more
|
European Urology - Prosthetic Nephrovesical Bypass
Wednesday, 25 October 2006
Volume 50, Issue 5, Pages 879-883 Article Outline: Patients with advanced malignant masses in the retroperitoneum often present with renal failure due to ureteral obstruction.
read more
|
√ Fatty Fish Consumption Associated with Decreased Risk of Renal Cancer in Women
Wednesday, 18 October 2006
√ Editor's Pick: BERKELEY, CA (UroToday.com) - The consumption of fatty fish such as salmon, herring, and mackerel has been associated with a reduction in the incidence of prostate cancer. This has not been previously studied in other urological malignancies.
read more
|
Wyeth Submits NDA and MAA for Torisel for the Treatment of Advanced Renal Cell Carcinoma
Monday, 09 October 2006
MADISON, NJ (PRESS RELEASE) -October 6, 2006 - First mTOR Inhibitor to Be Submitted for Cancer Indication - Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced today that the Company has initiated its global filing strategy for Torisel™ (temsirolimus) with the simultaneous submissions of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) and a marketing authorization application (MAA) to the European Medicines Agency (EMEA). The company is seeking an indication for the treatment of patients with advanced renal cell carcinoma (RCC).
read more
|
Percutaneous Renal Cryoablation
Monday, 09 October 2006
BERKELEY, CA (UroToday.com) - The treatment of small renal masses continues to evolve. From partial nephrectomy, to tissue ablative techniques performed in an open or laparoscopic fashion, to percutaneous renal cryoablation, urologists strive to be as minimally invasive as possible while not sacrificing oncologic results
read more
|
Outcome of Kidneys in Patients Treated for Vesicoureteral Reflux (VUR) During Childhood
Friday, 06 October 2006
BERKELEY, CA (UroToday.com) - The primary concern for patients with vesicoureteral reflux (VUR) is the development of renal impairment and hypertension. The aim of this study was to evaluate adult patients treated for VUR during childhood in regards to renal function and blood pressure (BP).
read more
|
√ Model Predicts Survival Time in Patients with Recurrent Renal Cell Carcinoma
Tuesday, 03 October 2006
√ Editor's Pick: BERKELEY, CA (UroToday.com) - In the July 1, 2006 issue of the Journal of Clinical Oncology, Dr. Eggener and associates at Memorial Sloan Kettering Cancer Center describe a model that stratifies patients with a recurrence of renal cell carcinoma (RCCA) by risk factors to predict survival time.
read more
|
Nexavar (Sorafenib, Bayer-Onyx) Found to Decrease Disease Progression When Compared with Placebo in Metastatic Renal Cancer
Tuesday, 03 October 2006
(Chicago, Illinois) - September 22-23, 2006 - FIFTH INTERNATIONAL KIDNEY CANCER SYMPOSIUM - Dr. Thomas Hudson presented data on Nexavar, the first drug approved by the FDA for the treatment of kidney cancer in the last 14 years.
read more
|
European Urology - Tissue Sealants in Lap
Monday, 02 October 2006
Volume 50, Issue 4, Pages 650-652 (October 2006) Thanks to the widespread diffusion of imaging techniques and health preventive programmes, the modern urologist is increasingly involved in the management of incidentally diagnosed renal masses.
read more
|
European Urology - Organ-Preserving Endoscopic Kidney Cancer Resection
Monday, 02 October 2006
Volume 50, Issue 4, Pages 732-737 (October 2006) Abstract - Objective: Recently, minimally invasive therapies for renal cell carcinoma have been devised to minimise operative morbidity yet achieve comparable oncologic and functional outcomes.
read more
|
European Urology - Prognostic Role of the Histologic Subtypes of Renal Cell Carcinoma after Slide Revision
Monday, 02 October 2006
Volume 50, Issue 4, Pages 786-794 (October 2006) Abstract -
Objectives:
To evaluate concordance, using the kappa statistic, between tumour histotypes assigned at initial diagnosis and those after slide revision, and to assess the independent predictive value of reviewed tumour histotype.
read more
|
European Urology - Efficacy of Ablative High-Dose-per-Fraction Radiation for Implanted Human Renal Cell Cancer in a Nude Mouse Model
Monday, 02 October 2006
Volume 50, Issue 4, Pages 795-800 (October 2006) Abstract -
Objectives:
Stereotactic body radiation therapy (SBRT) is a new therapeutic paradigm that uses a very large dose per fraction treatments (ablative hypofractionation). We investigated the use of ablative hypofractionation in treating human renal cell carcinoma using a nude mouse model.
read more
|
BJUI Mini Reviews - Low Penetrance Genetic Susceptibility to Kidney Cancer
Monday, 02 October 2006
In this review, a variablility in the metabolism of oestrogens might also be involved in the development of RCC in patients with hyperestrogeny as in overweight patients.
Login to read more...
|
Kidney Cancer Symposium - Nexavar (Sorafenib, Bayer-Onyx) Found to Decrease Disease Progression When Compared with Placebo in Metastatic Renal Cancer
Friday, 29 September 2006
Dr. Thomas Hudson presented data on Nexavar, the first drug approved by the FDA for the treatment of kidney cancer in the last 14 years.
read more
|
European Urology - Tumor Size Improves the Accuracy of TNM Predictions in Patients with Renal Cancer
Saturday, 23 September 2006
Volume 50, Issue 3, Pages 521-529 (September 2006) Abstract - Objectives: Current staging for renal cancer (RC) does not directly rely on tumor size. We examined the increment in accuracy related to inclusion of pathologically determined tumor size in prediction of nodal metastases (N+), distant metastases (M+), and cancer-specific survival (CSS).
read more
|
European Urology - Association of Mast Cells with Microvessel Density in Renal Cell Carcinomas
Thursday, 21 September 2006
Volume 50, Issue 3, Pages 530-534 (September 2006)
Abstract -
Background:
Growth of solid tumors requires angiogenesis. Evidence indicates that mast cells (MCs) play an important role in tumor angiogenesis.
read more
|
Simple Enucleation for the Treatment of PT1a Renal Cell Carcinoma: Our 20-Year Experience
Thursday, 21 September 2006
BERKELEY, CA (UroToday.com) - Adequate margins in partial nephrectomy continue to be a subject of debate in the literature, with newer studies challenging the dogma of a 10mm margin of normal tissue surrounding the tumor to maintain adequate oncologic control.
read more
|
Laparoscopic Partial Nephrectomy for Renal Masses: Effect of Tumor Location.
Monday, 18 September 2006
BERKELEY, CA (UroToday.com) - Not all small renal masses are created equal. This study demonstrates that not only size, but location, depth, and relation to the hilar vessels and collecting system all impact on the histopathology of the small renal lesion amenable to a partial nephrectomy.
read more
|
Results of Computerized Tomography Guided Percutaneous Ablation of Renal Masses With Nondiagnostic Pre-Ablation Pathological Findings
Friday, 15 September 2006
BERKELEY, CA (UroToday.com) - Considerable controversy surrounds the role of pre-ablation biopsies for renal masses scheduled for energy ablative strategies.
read more
|
Endocare Receives FDA 510K Clearance to Market New Nitrogen-Based Cryoablation System for Destroying Tissue and Cancerous Tumors
Wednesday, 13 September 2006
IRVINE, CA (Press Release) - September 2006 - Endocare, Inc. (OTC BB: ENDO), an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation, announced today that it has received 510K clearance from the U.S. Food and Drug Administration to market its new Cryocare CN2 System, a potentially much faster and easier-to-operate cryoablation system for freezing cancerous tumors and tissue.
read more
|
Masterclass for Urologists on Medical Tumor Treatment Held in Barcelona
Wednesday, 13 September 2006
ARNHEM, THE NETHERLANDS (Press Release) - September 2006 - A masterclass for practicing urologists who are involved in cancer care of urological patients is organized from 29 September to 1 October in Hotel Fira Palace in Barcelona, Spain.
read more
|
√ Nomogram to Predict The Risk Of Renal Insufficiency Following Radical Or Partial Nephrectomy
Wednesday, 13 September 2006
√ Editor's Pick: BERKELEY, CA (UroToday.com) - For many years, radical nephrectomy remained the gold standard for oncologic control of renal neoplasms.
read more
|
Hand Pain during Hand-Assisted Laparoscopic Nephrectomy – An Ischemic Event?
Tuesday, 12 September 2006
BERKELEY, CA (UroToday.com) - The ergonomics of minimally invasive urologic surgery has only recently garnered attention.
read more
|
Case Report: Management of Chylous Ascites Following Laparoscopic Nephrectomy with RPLND
Monday, 11 September 2006
BERKELEY, CA (UroToday.com) - Chylous ascites is an uncommon complication following retroperitoneal surgery, but can be quite problematic to manage.
read more
|
European Society for Urological Research to Host Congress in Malmo, Sweden
Friday, 08 September 2006
ARNHEM, THE NETHERLANDS (Press Release) - September 2006 - The European society for urological research (ESUR) will host its 17th congress in Malmö, Sweden from 14 to 16 September.
read more
|
What Is A Safe Margin In Partial Nephrectomy?
Friday, 08 September 2006
BERKELEY, CA (UroToday.com) - Traditionally, a one centimeter margin around any resected tumor has been the gold standard for oncology.
read more
|
Novel Approaches To Metastatic Renal Cell Carcinoma: Autologous Thymocytes Genetically Retargeted Against Carbonic Anhydrase IX.
Thursday, 07 September 2006
BERKELEY, CA (UroToday.com) - In this letter to the editor, Lamers and colleagues out of the Netherlands describe their initial experience with genetically retargeted autologous lymphocytes directed against carbonic anhydrase IX (CA9).
read more
|
The B7 Family of Co-regulatory Ligands Is Implicated Again in the Pathogenesis of Renal Cell Carcinoma Progression: B7-H4 Expression Predicts a Poor Outcome for Patients
Wednesday, 06 September 2006
BERKELEY, CA (UroToday.com) - Previous reports from the group at Mayo Clinic have demonstrated that B7-H1 expression by renal cell carcinoma (RCC) is a marker of poor prognosis in both localized and metastatic RCC.
read more
|
Venacavoscopy Assisted Inferior Vena Cava Thrombus Resection For T3b/c Renal Cell Carcinoma
Tuesday, 05 September 2006
BERKELEY, CA (UroToday.com) - Resection of intrahepatic and suprahepatic inferior vena cava (IVC) thrombi associated with renal cell carcinoma (RCC) can be surgically demanding procedures that can involve multidisciplinary surgical teams.
read more
|
New Developments in the Technique of Partial Nephrectomy
Friday, 01 September 2006
BERKELEY, CA (UroToday.com) - While partial nephrectomy has demonstrated oncologic equipoise with radical nephrectomy, it remains a surgically daunting procedure that can be associated with significant complications, particularly related to hemostasis and prevention of post-operative urinary fistulae.
read more
|
Circulating Tumor Cells in the Peripheral Blood of Patients with Renal Cell Carcinoma: RT-PCR Assays for Carbonic Anhydrase IX Expression Predict Risk of Disease Recurrence
Thursday, 31 August 2006
BERKELEY, CA (UroToday.com) - Investigations in a variety of tumor types have demonstrated that circulating tumor cells are present in the peripheral blood of patients, even those with what is thought to be otherwise localized disease, and can be prognostic of outcome.
read more
|
Tumor Specific Tissue Markers in Renal Cell Carcinoma: Kidney Specific Cadherin Falls Short of the Mark
Tuesday, 29 August 2006
BERKELEY, CA (UroToday.com) - The frequent inability to differentiate oncocytoma from chromophobe renal cell carcinoma (chRCC) from renal tumor biopsy material remains a large impediment to the increased utilization of renal tumor biopsy.
read more
|
Allogeneic Bone Marrow Transplantation For Metastatic Renal Cell Carcinoma: The European Experience
Monday, 28 August 2006
BERKELEY, CA (UroToday.com) - Allogeneic bone marrow transplantation is yet another treatment option for patients with metastatic renal cell carcinoma (mRCC), where initial reports by Childs out of the National Cancer Institute demonstrated significant disease responses.
read more
|
Comparing the Outcomes of Elective Partial to Radical Nephrectomy in Clear Cell Renal Cell Carcinoma 4-7 cm in Diameter
Thursday, 24 August 2006
BERKELEY, CA (UroToday.com) - In this report out of MSKCC, the authors report on 196 patients that underwent renal surgery for clear cell renal cell carcinoma (ccRCC) that measured 4-7 cm in diameter.
read more
|
24th WCE 2006 - Poster Session VP4
Wednesday, 23 August 2006
This video poster section contained 25 abstracts with highlighted topics such as the percutaneous management of uretropelvic junction obstruction (UPJO), ureteroscopic management of upper tract transitional cell carcinoma (UTTCC) and stone disease, These video posters were as eclectic as they were outstanding.
read more
|
Identifying the Molecular Mechanisms Behind the Invasive Phenotype in Renal Cell Carcinoma
Tuesday, 22 August 2006
BERKELEY, CA (UroToday.com) - Advances in new therapies for renal cell carcinoma (RCC) have come about as a consequence of a further understanding of the biology associated with local progression and metastasis.
read more
|
Does Involvement of the Collecting System by Energy Ablation Techniques Used to Treat Small Renal Masses Increase the Risk of Post-Procedural Complications?
Monday, 21 August 2006
BERKELEY, CA (UroToday.com) - Energy ablative strategies (percutaneous and laparoscopic) are being increasingly employed in the treatment of small renal masses.
read more
|
Laparoscopic Partial Nephrectomy Using the Potassium Titnyl Phosphate Laser in a Porcine Model
Monday, 21 August 2006
BERKELEY, CA (UroToday.com) - Working with an 80 watt KTP laser delivered in a noncontact mode via a 600 micron fiber, these authors successfully completed 15 laparoscopic partial nephrectomies in pigs. This was done without clamping any renal vessels.
read more
|
Survivin: A Tissue Marker of Poor Prognosis in Clear Cell Renal Cell Carcinoma
Friday, 18 August 2006
BERKELEY, CA (UroToday.com) - The search for molecular markers that further advance our knowledge of the biology of renal cell carcinoma (RCC) and assist in evaluating the diagnosis and prognosis of patients remains the subject of intense investigation.
read more
|
Collecting Duct Carcinoma: The Japanese Experience
Thursday, 17 August 2006
BERKELEY, CA (UroToday.com) - Collecting duct carcinoma is a rare and highly aggressive variant of renal cell carcinoma that frequently presents with advanced disease, has few effective treatment options, and is associated with a poor prognosis.
read more
|
Trying to Improve on the Activity of Interferon-Alpha in Metastatic Renal Cell Carcinoma: Interferon Plus Cimetidine in a Phase III Randomized Trial
Wednesday, 16 August 2006
BERKELEY, CA (UroToday.com) - - Interferon-alpha (IFN) has been a mainstay in the systemic treatment of metastatic renal cell carcinoma (RCC) for decades, with response rates ranging from 3-15%.
read more
|
Infiltration Of Renal Cell Carcinoma Primary Tumors By Mononuclear Cells Portends A Poor Prognosis
Friday, 11 August 2006
BERKELEY, CA (UroToday.com) - Renal cell carcinoma (RCC) has long been recognized to be an immunologically relevant tumor in part due to the histologic observation that immune cells are frequently found to infiltrate resected primary tumors.
read more
|
Size Doesn’t Matter!!! Size of a Negative Margin of Resection in Partial Nephrectomy has no Bearing on Patient Outcome
Wednesday, 09 August 2006
BERKELEY, CA (UroToday.com) - Traditional oncology dogma dictates that margins of resection are critical correlates to patient outcome.
read more
|
Novel Approaches To Metastatic Renal Cell Carcinoma: Autologous Thymocytes Genetically Retargeted Against Carbonic Anhydrase IX
Tuesday, 08 August 2006
BERKELEY, CA (UroToday.com) - In this letter to the editor, Lamers and colleagues out of the Netherlands describe their initial experience with genetically retargeted autologous lymphocytes directed against carbonic anhydrase IX (CA9).
read more
|
Renal Cancer 
